Background: Hippocampal sclerosis (HpScl) is common in elderly subjects with dementia, either alone or accompanied by other pathologic processes. It is also found in >70% of frontotemporal lobar degeneration with TDP-43 immunoreactive inclusions (FTLD-TDP). TDP-43 inclusions are detected in >20% of Alzheimer disease (AD) and >70% of HpScl cases. The most common cause of FTLD-TDP is mutation in the progranulin gene (GRN). Recently, a common genetic variant in the 3′ untranslated region (3′UTR) of GRN (rs5848; c.*78C>T) located in a microRNA binding site regulated progranulin expression, and the T-allele was increased in FTLD-TDP compared to controls. Objective: The goal of this study was to determine if the 3′UTR variant in GRN was associated with TDP-43 immunoreactivity in AD with and without HpScl. Methods: 644 cases of pathologically confirmed AD, including 57 with HpScl, were screened for TDP-43 immunoreactivity and were genotyped at the GRN 3′UTR single-nucleotide polymorphism rs5848 using previously published methods. Results: There was a trend (p = 0.06) for TDP-43 immunoreactivity, but a very significant (p = 0.005) association of HpScl with the variant, with 72% of AD with HpScl carrying a T-allele, compared to 51% of AD without HpScl carrying a T-allele. Conclusion: The results suggest that a genetic variant in GRN leading to decreased levels of progranulin may be a risk factor for HpScl in AD, while its role in TDP-43 immunoreactivity in AD remains less certain.
© 2010 S. Karger AG, Basel
- Alzheimer’s disease
- Hippocampal sclerosis
- Progranulin gene
- Dickson DW, Davies P, Bevona C, et al: Hippocampal sclerosis: a common pathological feature of dementia in very old (> or = 80 years of age) humans. Acta Neuropathol 1994;88:212–221.
- Zarow C, Sitzer TE, Chui HC: Understanding hippocampal sclerosis in the elderly: epidemiology, characterization, and diagnostic issues. Curr Neurol Neurosci Rep 2008;8:363–370.
- Hatanpaa KJ, Blass DM, Pletnikova O, et al: Most cases of dementia with hippocampal sclerosis may represent frontotemporal dementia. Neurology 2004;63:538–542.
- Blass DM, Hatanpaa KJ, Brandt J, et al: Dementia in hippocampal sclerosis resembles frontotemporal dementia more than Alzheimer disease. Neurology 2004;63:492–497.
- Josephs KA, Dickson DW: Hippocampal sclerosis in tau-negative frontotemporal lobar degeneration. Neurobiol Aging 2007;28:1718–1722.
- Petersen RC, Parisi JE, Dickson DW, et al: Neuropathologic features of amnestic mild cognitive impairment. Arch Neurol 2006;63:665–672.
- Sepe-Monti M, De Carolis A, Bomboi G, Castri P, Giubilei F: MRI evidence of bilateral hippocampal sclerosis in amnestic mild cognitive impairment. Eur J Neurol 2006;13:1031–1032.
- Kantarci K, Petersen RC, Przybelski SA, et al: Hippocampal volumes, proton magnetic resonance spectroscopy metabolites, and cerebrovascular disease in mild cognitive impairment subtypes. Arch Neurol 2008;65:1621–1628.
- Ala TA, Beh GO, Frey WH 2nd: Pure hippocampal sclerosis: a rare cause of dementia mimicking Alzheimer’s disease. Neurology 2000;54:843–848.
- Beach TG, Sue L, Scott S, et al: Hippocampal sclerosis dementia with tauopathy. Brain Pathol 2003;13:263–278.
- Togo T, Sahara N, Yen SH, et al: Argyrophilic grain disease is a sporadic 4-repeat tauopathy. J Neuropathol Exp Neurol 2002;61:547–556.
- Jicha GA, Petersen RC, Knopman DS, et al: Argyrophilic grain disease in demented subjects presenting initially with amnestic mild cognitive impairment. J Neuropathol Exp Neurol 2006;65:602–609.
- Obi T, Nishioka K, Ross OA, et al: Clinicopathologic study of a SNCA gene duplication patient with Parkinson disease and dementia. Neurology 2008;70:238–241.
- Farrer M, Kachergus J, Forno L, et al: Comparison of kindreds with parkinsonism and alpha-synuclein genomic multiplications. Ann Neurol 2004;55:174–179.
- Neumann M, Sampathu DM, Kwong LK, et al: Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 2006;314:130–133.
- Mackenzie IR, Neumann M, Bigio EH, et al: Nomenclature for neuropathologic subtypes of frontotemporal lobar degeneration: consensus recommendations. Acta Neuropathol 2009;117:15–18.
- Wang IF, Wu LS, Shen CK: TDP-43: an emerging new player in neurodegenerative diseases. Trends Mol Med 2008;14:479–485.
- Amador-Ortiz C, Lin WL, Ahmed Z, et al: TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimer’s disease. Ann Neurol 2007;61:435–445.
- Hasegawa M, Arai T, Nonaka T, et al: Phosphorylated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Ann Neurol 2008;64:60–70.
- Probst A, Taylor KI, Tolnay M: Hippocampal sclerosis dementia: a reappraisal. Acta Neuropathol 2007;114:335–345.
- Baker M, Mackenzie IR, Pickering-Brown SM, et al: Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature 2006;442:916–919.
- Cruts M, Gijselinck I, van der Zee J, et al: Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. Nature 2006;442:920–924.
- Gass J, Cannon A, Mackenzie IR, et al: Mutations in progranulin are a major cause of ubiquitin-positive frontotemporal lobar degeneration. Hum Mol Genet 2006;15:2988–3001.
- Josephs KA, Ahmed Z, Katsuse O, et al: Neuropathologic features of frontotemporal lobar degeneration with ubiquitin-positive inclusions with progranulin gene (PGRN) mutations. J Neuropathol Exp Neurol 2007;66:142–151.
- Mackenzie IR, Baker M, Pickering-Brown S, et al: The neuropathology of frontotemporal lobar degeneration caused by mutations in the progranulin gene. Brain 2006;129:3081–3090.
- Rademakers R, Eriksen JL, Baker M, et al: Common variation in the miR-659 binding-site of GRN is a major risk factor for TDP43-positive frontotemporal dementia. Hum Mol Genet 2008;17:3631–3642.
- Luis CA, Barker WW, Gajaraj K, et al: Sensitivity and specificity of three clinical criteria for dementia with Lewy bodies in an autopsy-verified sample. Int J Geriatr Psychiatry 1999;14:526–533.
- He Z, Bateman A: Progranulin (granulin-epithelin precursor, PC-cell-derived growth factor, acrogranin) mediates tissue repair and tumorigenesis. J Mol Med 2003;81:600–612.
- Bhandari V, Palfree RG, Bateman A: Isolation and sequence of the granulin precursor cDNA from human bone marrow reveals tandem cysteine-rich granulin domains. Proc Natl Acad Sci USA 1992;89:1715–1719.
- Bateman A, Belcourt D, Bennett H, Lazure C, Solomon S: Granulins, a novel class of peptide from leukocytes. Biochem Biophys Res Commun 1990;173:1161–1168.
- Ahmed Z, Mackenzie IR, Hutton ML, Dickson DW: Progranulin in frontotemporal lobar degeneration and neuroinflammation. J Neuroinflammation 2007;4:7.
- Polymeropoulos MH, Lavedan C, Leroy E, et al: Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease. Science 1997;276:2045–2047.
- Maraganore DM, de Andrade M, Elbaz A, et al: Collaborative analysis of alpha-synuclein gene promoter variability and Parkinson disease. JAMA 2006;296:661–670.
- He L, Hannon GJ: MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet 2004;5:522–531.
- Carthew RW, Sontheimer EJ: Origins and mechanisms of miRNAs and siRNAs. Cell 2009;136:642–655.
- Dickson DW: TDP-43 immunoreactivity in neurodegenerative disorders: disease versus mechanism specificity. Acta Neuropathol 2008;115:147–149.
Dennis W. Dickson, MD
Department of Neuroscience, Mayo Clinic
4500 San Pablo Road
Jacksonville, FL 32224 (USA)
Tel. +1 904 953 7137, Fax +1 904 953 7117, E-Mail firstname.lastname@example.org
Published online: March 3, 2010
Number of Print Pages : 5
Number of Figures : 1, Number of Tables : 1, Number of References : 36
Vol. 7, No. 1-3, Year 2010 (Cover Date: April 2010)
Journal Editor: Nitsch R.M. (Zürich), Hock C. (Zürich)
ISSN: 1660-2854 (Print), eISSN: 1660-2862 (Online)
For additional information: http://www.karger.com/NDD
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.